Taiwan-based vaccine maker Medigen will conduct a Phase 3 clinical trial for its COVID-19 vaccine in Europe once it has received approval from European authorities, which would help pave the way for its entry into European and other international markets, the company announced Wednesday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Ex-USAID adviser hopes Taiwan partnership endures amid uncertainty
02/28/2025 05:37 PM - Cross-Strait
Taiwan bans exchanges with 7 Chinese universities over security concerns
02/28/2025 05:18 PM - Business
Taiwan, Finland sign air service agreement
02/28/2025 05:02 PM - Culture
Minor planet named after iconic Taiwanese artist
02/28/2025 03:53 PM - Society
Taiwan's population centers endure 2nd day of severe air pollution
02/28/2025 02:42 PM